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Diabetes mellitus and latent tuberculosis infection: cross-sectional study within a 












Individuals aged ≥16 years were invited to take part in the study through two strategies 
targeting high-risk groups between January 2011 and July 2015. Firstly, contacts of active 
TB cases (“contacts”) were invited to participate when attending appointments for TB 
screening (contacts are screened for active TB and LTBI as part of the routine public health 
response to active TB cases in the UK). Secondly, recent entrants to the UK were recruited 
through the registers of participating general practitioners and mass recruitment events in 
community settings such as places of worship. Recent entrants were eligible to participate if 
they entered the UK from a high incidence country (≥40 per 100,000 based on WHO data 
(12)) within the last five years and/or made frequent visits to a high incidence country (at 
least one year cumulatively spent in a high incidence country over the previous five years). 
Some recent entrants were also recruited through the same process as contacts, after 
referral following entry screening. Participants were recruited primarily in London, but also in 
Birmingham and Leicester. Participants with evidence of active TB at baseline were 
excluded.  
 
Before recruitment, potential participants were asked screening questions to identify signs of 
possible TB (night sweats, unintended weight loss, or persistent cough). Individuals reporting 






Exposure, outcome and covariates 
Questionnaire completion was assisted by study nurses and translators were provided if 
necessary. 
 
The main exposure of interest was a self-reported history of DM. Data were also collected on 
the method of DM control used (categorised as monitoring and/or diet only, oral 
hypoglycaemic medications, or insulin). Other self-reported covariates investigated were 
sex, age, country of birth (UK or elsewhere), ethnicity (classified according to standard 
practice in the UK’s Enhanced Tuberculosis Surveillance system), previous BCG vaccination 
(confirmed by sight of scar), previous TB diagnosis, previous contact with a TB patient (for 
contacts, this means contacts prior to the one resulting in recruitment to the study), HIV 
status, other immunosuppression, smoking status (never or ever smoker), social risk factors, 
and type of participant (contact or new entrant). Body mass index (BMI) was calculated as 
weight(kg)/height(m)2, with weight and height being either self-reported or measured by 
study nurses. 
 
Participants were considered to have “other immunosuppression” if they reported a history of 
using anti-TNF- or other immunosuppressive drugs, solid organ transplant, haematological 
malignancy, jejuno-ileal bypass, chronic renal failure or haemodialysis, or gastrectomy. 
Social risk factors considered were current or past homelessness, imprisonment or problem 
drug use; participants were classified as having either no social risk factors or any social risk 
factor. 
 
The outcome of interest was LTBI, defined as having a positive result for either or both of the 
two commercially available IGRAs, Quantiferon-TB Gold In-Tube (QFT-GIT – Qiagen) and 
TSpot.TB (Oxford Immunotec, Abingdon, UK). Each IGRA result was recorded as positive, 
negative or indeterminate according to the manufacturer’s instructions (TSpot.TB can 
additionally generate borderline positive and borderline negative results, which were treated 
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as positive and negative, respectively). Participants usually received both IGRAs; however in 
some cases, notably community recruitment events, only the QFT-GIT was administered. 
Those who were negative on both assays, or negative on one and indeterminate on the 
other, were considered not to have LTBI. Participants with no valid IGRA results were 




The sample size for the current cross-sectional analysis was determined by the number of 
participants recruited to PREDICT. Given that data were available for 756 diabetic and 8401 
non-diabetic participants, we estimated that we would have 98% power to detect a difference 




Binomial regression with a log link was used to estimate crude and adjusted prevalence 
ratios (PRs) and 95% CIs for the relationship between DM and LTBI (16). The outcome 
(LTBI) was common in the PREDICT cohort (approximately 28%), reflecting the targeted 
high-risk population, so odds ratios generated by logistic regression would not approximate 
the prevalence ratio (16). For multivariable modelling, age and sex were treated as a priori 
confounders. Other covariates for adjustment were identified from a causal diagram of the 
relationships between potential confounders and outcomes using directed acyclic graphs, 
interpreted using dagitty.net (17) (Supplementary Figure 1). P values were derived from 
likelihood ratio tests. We assessed potential interactions between DM and age (4) and DM 





Age group was treated as a categorical variable (16-25, 26-35, 36-45 and >45 years) as this 
produced the best fit in univariate analysis (based on likelihood ratio tests comparing models 
using either continuous age or a linear term for age group). BMI was also treated as a 
categorical variable, classified as <18.5kg/m2, 18.5-25kg/m2 and ≥25kg/m2 (underweight, 
normal weight and overweight, respectively). 
 
We conducted five sensitivity analyses. Firstly, we adjusted for age as a continuous variable 
using fractional polynomials (19). Secondly, we repeated the primary analysis using Poisson 
regression with robust standard errors instead of log-binomial regression (20), as there is 
debate about which of these methods is more appropriate for modelling epidemiological 
associations when the outcome is common (21-23) (p values here were derived from Wald 
tests, as likelihood ratio tests cannot be used with robust standard errors). Thirdly, we 
restricted the analysis to contacts of active TB cases. In these participants, any LTBI is likely 
to be a result of recent infection, whereas recent entrants to the UK may have been infected 
many years ago in their country of origin. Fourthly, we included only participants who had 
concordant results for the two IGRAs. Finally, we repeated the primary analysis additionally 




713 participants were excluded from the analysis due to missing data on DM and/or LTBI 
status (Figure S1). Those who were included in the analysis were more likely to be male, 
aged 26-45 years and new entrants than those who were excluded (Table S1). There were 
also differences in ethnicity, with a higher percentage of participants of Pakistani, 
Bangladeshi and Mixed ethnicity, and a lower percentage of individuals of Indian ethnicity, in 





Table S1: Comparison of participants who were included in the analysis and those who were 
excluded due to missing data on diabetes and / or IGRA status 





Total  9157 713  
     
Sex Male 4555 (50.0) 317 (45.9) 0.039 
(n = 9797) Female 4552 (50.0) 373 (54.1)  
     
Age group  16-25 2257 (24.7) 176 (25.4) 0.009 
(years) 26-35 3145 (34.4) 208 (30.0)  
(n = 9846) 36-45 1419 (15.5) 97 (14.0)  
 >45 2331 (25.5) 213 (30.7)  
     
Country of birth Non-UK 7664 (83.9) 567 (82.3) 0.26 
(n = 9820) UK 1467 (16.1) 122 (17.7)  
     
Ethnicity Indian 3759 (42.1) 328 (48.0) <0.001 
(n = 9618) White 1112 (12.5) 85 (12.4)  
 Black African 1090 (12.2) 94 (13.7)  
 Mixed 873 (9.8) 57 (8.3)  
 Pakistani 878 (9.8) 51 (7.5)  
 Bangladeshi 695 (7.8) 23 (3.4)  
 Black Caribbean 220 (2.5) 27 (4.0)  
 Black Other / 
Chinese / Other 
307 (3.4) 19 (2.8)  
     
Type of participant Contact 4670 (51.0) 429 (60.2) <0.001 
(n = 9870) New entrant 4487 (49.0) 284 (39.8)  
     
Previous BCG 
vaccination 
No 1418 (18.3) 98 (17.7) 0.74 
(n = 8312) Yes 6341 (81.7) 455 (82.3)  
     
Previous TB 
diagnosis 
No 8689 (96.4) 638 (95.2) 0.11 
(n = 9682) Yes 323 (3.6) 32 (4.8)  
     
Previous contact with 
TB case 
No 7679 (86.9) 576 (88.1) 0.40 
(n = 9487) Yes 1154 (13.1) 78 (11.9)  
     
HIV positive No 8487 (99.4) 641 (9.5) 0.65 
(n = 9183) Yes 52 (0.6) 3 (0.5)  
     
Other 
immunosuppressiona  
No 8908 (97.4) 662 (97.6) 0.65 
(n = 9828) Yes 242 (2.6) 16 (2.4)  
     
Smoking No 7390 (81.0) 558 (82.4) 0.36 
(n = 9802) Yes 1735 (19.0) 119 (17.6)  
     
BMI (kg/m2) <18.5 430 (5.0) 29 (4.7) 0.32 
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(n = 9204) 18.5 – 25  4224 (49.2) 285 (46.3)  
 ≥25 3935 (45.8) 301 (48.9)  
     
Any social risk  No 8735 (95.4) 688 (96.5) 0.17 
factorb (n = 9870) Yes 422 (4.6) 25 (3.5)  
 
a Other immunosuppressive factors considered were: history of using anti-TNF- or other 
immunosuppressive drugs, solid organ transplant, haematological malignancy, 
jejunoilealbypass, chronic renal failure or haemodialysis, gastrectomy. 
b Social risk factors considered were: current or past homelessness, imprisonment or 
problem drug use. 
 
 





Table S2: Adjusted prevalence ratios for the association of diabetes mellitus and other 
baseline characteristics with latent tuberculosis infection from multivariate log binomial 
model (n = 8336) 
  Prevalence ratio 
(95% CI) 
p 
Diabetes No Referent  
 Yes 1.15 (1.02-1.30) 0.025 
    
Sex Male Referent  
 Female 0.80 (0.74-0.85) <0.001 
    
Age group 16-25 Referent  
(years) 26-35 1.27 (1.15-1.41)  
 36-45 1.47 (1.31-1.65)  
 >45 1.32 (1.17-1.48) <0.001 
    
Ethnicity Indian Referent  
 White 0.81 (0.71-0.92)  
 Black African 1.40 (1.27-1.54)  
 Mixed 1.20 (1.07-1.34)  
 Pakistani 1.15 (1.02-1.29)  
 Bangladeshi 0.72 (0.61-0.85)  
 Black Caribbean 0.68 (0.50-0.93)  
 Black Other / Chinese / Other 0.97 (0.79-1.19) <0.001 
    
Other  No Referent  
immunosuppressiona Yes 0.75 (0.57-0.97) 0.02 
    
BMI (kg/m2) <18.5 Referent  
 18.5 – 25  0.97 (0.82-1.14)  
 ≥25 0.93 (0.79-1.10) 0.52 
a Other immunosuppressive factors considered were: history of using anti-TNF- or other 
immunosuppressive drugs, solid organ transplant, haematological malignancy, 
jejunoilealbypass, chronic renal failure or haemodialysis, gastrectomy. 
 
 





Table S3: Estimated prevalence ratios for the association of diabetes mellitus with latent 
tuberculosis infection by ethnicity, adjusted for age group, sex, BMI category and 
immunosuppression. 
 
Ethnicity Prevalence ratio 
(95% CI) 
p 
Indian 1.00 (0.85-1.18) 0.96 
White 0.58 (0.23-1.46) 0.25 
Black African 1.48 (1.16-1.90) 0.002 
Mixed 1.37 (0.95-1.98) 0.09 
Pakistani 1.41 (1.01-1.99) 0.05 
Bangladeshi 1.53 (0.91-2.57) 0.11 
Black Caribbean 1.26 (0.57-2.78) 0.57 
Black other, Chinese or Other 1.78 (0.97-3.26) 0.06 
 
 
Table S4 summarises the results of sensitivity analyses. 
 
Table S4: Adjusted prevalence ratios for the association between diabetes mellitus and 
latent tuberculosis infection from multivariate log binomial model, in sensitivity analyses. All 
estimates are adjusted for sex, age group, ethnicity, other immunosuppression and BMI. 
 
Sensitivity analysis n Prevalence ratio 
(95% CI) 
p 
Adjusted for age using 
fractional polynomials 
8336 1.15 (1.01-1.30) 0.04 
Poisson regression with 
robust standard errors 
8336 1.15 (1.01-1.30) 0.03 
Restricted to participants 
with concordant IGRA results 
6300 1.16 (0.97-1.40) 0.11 
Restricted to contacts 4238 1.29 (1.09-1.52) 0.002 
Further adjusted for country 
of birth 




Figure S1: Causal diagram summarising the relationship between diabetes mellitus, latent tuberculosis infection and relevant covariates. Direct 
relationships between covariates and LTBI are shown by solid black lines, between covariates and DM by dashed black lines, other 
relationships by grey lines. 































The UK Prognostic Study of the Interferon Gamma 
Release Assay for Tuberculosis 
 
 
Thank you for your help with this research. The questionnaire will take approximately 10 minutes to 
complete. If you need any help please feel free to contact: xxx. 
 
Please read each question carefully before you answer it, and try to answer every question. Either 
tick the appropriate box or write your answer in the space provided in BLOCK CAPITALS. 
 











NHS number: ……………………………………… Local Patient ID: ……………………………………. 
 
 
c) Address/telephone number 
 
Address line one: ………………………………………………. 
 
Address line two:  ………………………………………………. 
 
Town:    ………………………………………………. 
 
County:   ………………………………………………. 
 
Post code:   ………………………………………………. 
 
Telephone Number: ……………………………………………… 
 
 
d) Locality of patient care 
 
Primary Care Trust or Local Health Board (of patient’s residence): …………………………………… 
 
Local Authority of patient’s residence: …………………………………………………………………... 
 
Participant’s consultant: …………………………………………………………………………………... 
 













Date of birth: ……………………………. (day/month/year) Age: ……………………………. (years) 
 
c) Were you born in the UK? 
 
 Yes          No   Not sure 
 
If non UK born please state country of birth: ……………………………. 
 
If non UK born please state date of entry to the UK: ……………………………. (month/year) 
 
Country of residence prior to arrival in the UK: ……………………………. 
 
 
d) Current or most recent job? 
Health care worker: 
 Doctor      Nurse     
 Dentist      Community care worker  
 Other      
 
Social/Prison sector worker: 
 Social worker     Homeless sector worker  
 Prison Detention Officer   Probation Officer   
 Other   
    
Laboratory/pathology: 
 Microbiologist     Laboratory staff   
 Pathologist     PM attendant    
 Other  
     
Agricultural/animal care worker: 
 Works with cattle    Works with wild animals   
 Other  
     
Education: 
 Full time Student    Lecturer    
 Teacher (inc Nursery)    Other  
   
None: 
 Retired     Unemployed    
 Child      Prisoner    
 House wife/husband    Immigration Detainee   
 Asylum seeker    Other     
 
Other: ……………………………………..   
 
Not sure       
 
e) Ethnicity 
 White      Indian   
 Black African     Pakistani  
 Black Caribbean    Bangladeshi  
 Black Other     Chinese  





a) Contact criteria- indicate as appropriate* 
 








Within 3 feet?  
 
Volume of room? 
 
 






Within 3 feet?  
 
Volume of room? 
 
 
Education Secondary, tertiary Same 
class? 
Within 3 feet?  
 
Volume of room? 
 
 




Within 3 feet?  
 
Volume of room? 
 
 
Homeless Residential hostel, 
night shelter, sofa 






Within 3 feet?  
 











Within 3 feet?  
 
Volume of room? 
 
 





Within 3 feet?  
 
Volume of room? 
 
 
Workplace/social Indoor or outdoor type: 
factory, crack house, 
restaurant, pub/bar, 






Other     
 
* To also collect information on sputum and culture result of index case 
Adapted from Shams et al., and UK contact tracing module 
 
 
When did you last have contact with this person?: ………………. (day/month/year)      / Not Known  
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b) Prior to this recent contact, have you previously had contact with anyone else diagnosed 
with tuberculosis? 
 




 Household     Non-household 
 
How many years ago: ……………………………. 
 
 
c) Have you previously received a diagnosis of tuberculosis? 
 
 Yes          No   Not sure 
 
If yes, how many years ago: ……………………………. 
 
If yes, were you treated with at least 1 month of drug therapy? 
 
 Yes          No   Not sure 
 
 
Medical and Social History 
 
a) Do you have a history of problem drug use? 
 
 Yes          No   Not sure 
 
If yes, please select one or more categories: 
 
 Current drug use        Drug use in the last 5 years       Drug use more than 5 years ago 
 
 
b) Are you currently homeless or ever been homeless? 
 
 Yes          No   Not sure 
 
If yes, please select one or more categories: 
 
 Currently Homeless    Homeless in the last 5 years    Homeless more than 5 years ago 
 
 
c) Have you ever been in prison? 
 
 Yes          No   Not sure 
 
If yes, please select one or more categories: 
 





d) Do you have a history of diabetes? 
 
 Yes          No   Not sure 
 
If yes, please state level of control:  ….….…. 
 
 
e) Do you have a history of cancer? 
 
 Yes          No   Not sure 
 
If yes, please state type:  ….….…. 
 
 
f) Are you HIV positive? 
 
 Yes          No   Not sure 
 
 
g) Do you have a history of smoking? 
 
 Yes          No   Not sure 
 
If yes, please state how many a day and for how long:  ….….…. 
 
h) Do you have a history of, or currently use, any of the following? 
 
 Yes No Unknown Type Amount 
Previous Transplant      
Anti-TNF alpha      
Steroids       
Immunosuppressive Drugs       
 
 
i) Have you previously received a BCG vaccination? 
 
 Yes          No   Not sure 
 
If yes, approximate year of vaccination:  ….….…. 
 
j) Have you travelled outside the UK in the last three years (please do not include travel to 
Western Europe, US, Canada and Australia)? 
 
 Yes          No   Not sure 
 
Please list where you travelled to with dates 
 
Place Date Duration 
   
   




k) Have you travelled or lived in any of these places before the three years (please do not 
include travel to Western Europe, US, Canada and Australia)? 
 
 Yes          No   Not sure 




By placing a tick in one box in each group below,  
please indicate which statements best describe your own health state today  
 
Mobility 
I have no problems in walking about   
I have some problems in walking about  
I am confined to bed  
   
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
   
Usual activities 
 (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual acitivities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
   
Pain or discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
   
Anxiety or depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
   
 
Thank you for taking the time to fill in this questionnaire. Please return this questionnaire to the 
research nurse 
 
For Official Use only 
Name of Research Nurse: 
 
Please enter study number: 
 




For Official Use Only 
 
Weight:  ….….…………………….. kgs 
 
Height:  ….….…………………….. metres 
 
 
Results of laboratory tests 
 
Type of test Test Unit Type 
IGRA (*2) Quantiferon iu/ml Numerical 
 ELISPOT Spots Numerical 
Full Blood Count White Blood Cells 
(Leukocytes) 
No/ml Numerical 
 Red cells No/ml Numerical 
 Platelets No/ml Numerical 
 Haemoglobin mg/ml Numerical 





Vitamin D status 25 Hydroxyvitamin D ng/ml or nmols/L Numerical 
TST  Mantoux test mm Numerical 
 
 
 
 
 
